Despite advances in cancer treatment, metastasis remains today the main cause of cancer death. Local control through complete surgical resection of the primary tumor continues to be a key principle in cancer treatment. However, surgical interventions themselves lead to adverse oncologic outcomes and are associated with significantly increased rates of metastasis. Neutrophils through release of neutrophil extracellular traps (NETs) in response to infections were shown to be able to capture circulating cancer cells, and in doing so, support the development of metastatic disease. To be able to intervene on this process, understanding the exact molecular nature of these mechanisms is crucial. We therefore hypothesize and demonstrate that b1-integrin is an important factor mediating the interactions between circulating tumor cells and NETs. We show that b1-integrin expression on both cancer cells and NETs is important for the adhesion of circulating tumor cells to NETs both in vitro and in vivo. Using a murine model of intra-abdominal sepsis to mimic the postoperative inflammatory environment, we show that b1-integrin expression is upregulated in the context of inflammation in vivo. Ultimately, we show that this increased early cancer cell adhesion to NETs in vivo and this effect is abrogated when mice are administered DNAse 1. Our data therefore sheds light on the first molecular mechanism by which NETs can trap circulating tumor cells (CTCs), broadening our understanding of this process.
Introduction
Tumor recurrence after curative intent surgery remains an important and frequent clinical problem and presents an economic burden, a treatment challenge as well as a heavy psychological load on affected patients. It has been shown that patients who suffered from postoperative complications had a significant decrease in 5-year survival and/or disease free survival compared to those who did not. [1] [2] [3] This decrease was shown to be driven by infective complications 2 and postoperative complication has been shown to be a prognostic indicator for early recurrence. 4, 5 Along the same lines, anastomotic leak in patients undergoing restorative surgery for colorectal tumors was associated with worse oncologic outcomes. 6 Attention was quickly drawn to neutrophils as they constitute the vast majority of circulating white blood cells in the context of infection. 7 Accordingly, high levels of circulating neutrophils [8] [9] [10] [11] as well as neutrophil to lymphocyte ratio [12] [13] [14] [15] [16] [17] [18] were both shown to be associated with worse oncological outcomes in patients with a variety of solid organ tumors. Neutrophils were found, under specific stimuli, to have the unique ability to form Neutrophil Extracellular Traps (NETs). 19, 20 This process, also termed NETosis results in local formation of web-like projections of extracellular decondensed chromatin DNA decorated by numerous neutrophilderived histones and peptides. NETs have already been found to be involved in a variety of physiological as well as disease processes. [19] [20] [21] [22] [23] Cancer was shown to predispose circulating neutrophils to secrete NETs 24 and NETs were able to enhance both proliferation and malignant transformation of B cells in the context of autoimmune diseases. 25 A possible link between the presence of NETs and poor oncologic outcomes was seen in 26 and along those lines, we were able to show that NETs are able to capture circulating tumor cells (CTCs) causing their arrest in the circulation and secondary adhesion to distant organs. 27 Tumorigenesis requires number of essential steps such as tumor initiation, migration and proliferation that are part of the integrin family essential functions. 28 In fact, integrins have been found to be overexpressed in a number of different cancer types. 29 Along those lines, the idea of using integrin expression as a prognostic factor in cancer rose, and many studies looked for potential correlations between integrin expression on tumors and oncologic outcomes. [30] [31] [32] Similar prognostic correlations with different integrin subtypes have been shown in breast, 33 prostate, 34 colon 35 cancers as well as others. 29 Integrin function is therefore now recognized as an important contributing factor in tumor development and spread and a large body of work had been looking at developing a variety of selective carrier systems for tumor integrin targeting as a therapeutic tool. 36 Given this close intermingled relationship between integrins and cancer and the newly identified role of NETs in capturing circulating tumor cells which then lead to increased metastasis, we sought to investigate whether integrins can be the potential link in the interaction between NETs and circulating cancer cells, looking more specifically at the role of b1 integrins.
Materials and Methods

Cell lines
Human A549 lung carcinoma cells were purchased from ATCC and maintained in DMEM F12 media supplemented with 10% FBS and 100 lg/mL Pen/Strep (all from Wisent Bioproducts, StBruno, QC, Canada). Murine Lewis Lung carcinoma cell subline H59, expressing stable GFP were a kind gift of Dr. Pnina Brodt 37 and maintained in RPMI with 10% FBS, 100 lg/mL Pen/Strep and 300 lg/mL glutamine (all from Wisent Bioproducts).
Human peripheral blood neutrophil isolation
Human neutrophil isolation is described in ref. [38] . Briefly, blood was diluted in PBS (Wisent Bioproducts) and layered over Lymphocyte Separation Media (Wisent Bioproducts). After centrifugation at 800 g for 30 min at room temperature (RT), the pellet containing neutrophils and red blood cells (RBCs) was collected and resuspended in 3% Dextran (Spectrum Chemicals) and left at RT to sediment RBCs. After 30 min, the supernatant is collected and centrifuged at 480 g at 48C for 5 min. Remaining RBCs in the neutrophil rich pellet are then lysed using BD Pharm Lyse Lysing buffer (BD Biosciences). The obtained pellet is then washed and resuspended in cold RPMI media (Wisent Bioproducts) containing 3% FBS. Purity and viability of the obtained neutrophils were verified through Methylene blue (Stem cell Technologies, Vancouver, BC, Canada) and Trypan blue (Wisent Bioproducts) staining respectively.
Mouse bone marrow neutrophil isolation
Mouse neutrophils isolation is described in ref. [39] . Briefly, mice were sacrified and their tibias and femurs dissected and their bone marrow flushed using HBSS with Phenol red supplemented with 0.5% FBS and 20 mM HEPES (all from Wisent Bioproducts) (referred to as HBSS prep) and passed through a 70 lm cell strainer. RBCs were then lysed using BD Pharm Lyse Lysing buffer. Neutrophils were then separated by layering the neutrophil containing solution over a Percoll gradient (62% v:v in HBSS, Sigma Aldrich) and centrifuging the layered solution at 1,000 g for 30 min at 48C. Neutrophils were retrieved from the pellet and resuspended in HBSS prep.
NETs generation
NETs were generated as previously described in ref. [38] . Briefly, isolated neutrophils were stimulated with 500 nM of PMA (Sigma Aldrich) and allowed to NETose for 4 hr at 378C, 5% CO 2 and then centrifuged at 480 g to pellet neutrophils, leaving a NET-rich supernatant that was spun at 18,000 g to pellet the NETs. The obtained NETs pellet was resuspended in cold PBS.
Antibodies for imaging
See supplemental Table S1 .
Western blotting
A549 cells were stimulated with NETs, washed with PBS and lysed with 50 mM Tris-HCl pH7.5, 1 mM EGTA, 1 mM EDTA, 1% Triton X-100, 1 mM sodium orthovanadate, 50 mM Sodium fluoride, 5 mM sodium pyrophosphate, 0.27 M Sucrose, protease inhibitors (Pierce PI88666)). 25 mg of proteins were loaded on 10% SDS-PAGE, transferred on nitrocellulose. The membranes were blocked for 1 hr in 5% milk-TBS and probed overnight at 48C with the appropriate set of primary/secondary antibodies (see supplemental Table S1 ) and imaged using a LiCor scanner. Alternatively, to detect integrin b1 on NETs, cell-free NETs were loaded onto an SDS-PAGE gel and then same procedure performed as above-mentioned with the appropriate antibodies (see supplemental Fig. S1 ).
Flow cytometry
Cells were incubated in 1% FBS in PBS with FITC conjugated mouse anti-human CD29 antibody (Beckman Coulter) or FITC-conjugated mouse IgG1 (cedarlane) using 2.5 mg/10 6 cells for 30 min. The cells were then washed with PBS and immediately analyzed by flow cytometry using FACScan and CellQuest Software for analysis.
b1 siRNA transfection technique 60 pmol of b1 siRNA or control siRNA (siRNA kit, Santa Cruz Biotechnology) were used to transfect A549 cell as per What's new? Surgical removal of tumors can increase inflammation. When neutrophils respond to inflammatory signals, they sometimes form web-like projections called "neutrophil extracellular traps" (NETs). These NETs are able to enhance metastasis, because they bind circulating tumor cells (CTCs) and cause them to adhere to distant organs. In our study, the authors found that b1-integrins play an essential role in the interaction between NETs and tumor cells. Then, they found that hepatic adhesion of CTCs in mice could be significantly reduced by blocking b1-integrins. These results suggest that targeting b1-integrins may help to reduce metastases. kit instructions. Transfection efficiency was monitored using fluorescein-conjugated siRNA per provided instructions and successful integrin b1 silencing was verified by flow cytometry.
In vitro adhesion assays
The in vitro adhesion assay is previously described in ref. [38] . In the experiments where integrin b1 was blocked on either NETs or cancer cells prior to quantification of adhesion, either the NET stock or the cancer cells were preincubated for 1 hr at 378C with 20 lg of 4B4 anti-CD29 antibody (Beckman Coulter, Mississauga, ON, Canada) or mouse IgG 1 isotype control (Abcam).
Immunofluorescence
NETs were added on 13 mm glass coverslips (Fisher Scientific) and allowed to adhere overnight at 48C. 3 3 10 5 A549 cells were added on the coverslips for 90 min at 378C followed by a gentle wash. Coverslips were then fixed using 4% PFA for 10 min at RT followed by another gentle wash. 1% BSA was then added for 1 hr at RT followed by anti-CD29 (4B4) antibody or mouse IgG1 isotype control antibody (both at 1:100) followed by a gentle wash, then FITC-conjugated goat-anti mouse IgG (1:100) was added. In experiments where extracellular DNA was also stained, 5 lM of Sytox orange was then added onto coverslips for 10 min at RT. All coverslips were mounted on microscope slides using Mowiol mounting media (Sigma Aldrich) and visualized using LSM 780 laser scanning confocal microscope (Zeiss, Dorval, QC, Canada). For experiments assessing FAK phosphorylation, coverslips coated with NETs and A549 cells were incubated with anti-p-FAK tyr 397 primary antibody (1:50, Santa Cruz Biotechnology) followed by incubation with Alexa-fluor 647 goat-anti mouse IgG secondary antibody (1:200, Molecular Probes).
Integrin co-localization experiment 2 3 10 5 A549 cells were plated onto 13 mm glass coverslips to form a monolayer for 1 hr at 378C. A549 cells were preincubated for 1 hr with either 20 lg anti-CD29 antibody (4B4) or Alexa-fluor 647 labeled anti b1 integrin (1:100, Santa Cruz) or mouse IgG1 isotype control prior to their addition on coverslips, followed by washing with PBS. NETderived b1 integrin was stained with Alexa-fluor 555 anti b1 integrin (1:100, Abcam) for 1 hr at RT in the dark and washed with PBS then added to the A549 monolayer for 1 hr, after which it was washed with PBS. 1000 U of DNAse 1 was added onto each coverslip followed by a wash. Coverslips were mounted using Mowiol mounting media for visualization using a Zeiss LSM 780 laser scanning confocal microscope.
Animals
7-10 weeks old C57BL/6 male mice (Charles River) were used for all experiments. Intra-abdominal sepsis was achieved using the CLP model as previously described. 27, 40 All animal experiments were performed in accordance with the McGill University Animal Care Committee guidelines.
Intravital microscopy (IVM)
Mice were anesthetized by intraperitoneal injection of a mixture of 50 mg/kg ketamine (Wyeth Ayerst, Canada, SaintLaurent, QC, Canada) and 5 mg/kg Xylazine (Bayer, Canada). 10 5 CFSE-labeled cancer cells were injected intrasplenically and adhesion to liver sinusoids visualized after 20 min. In other experiments, right jugular vein access was obtained for maintenance of anaesthesia and left internal carotid artery cannulation performed for administration of fluorescent dyes and cancer cells. The left lobe of the liver was positioned on a glass coverslip over the microscope objective. When spinning disk confocal IVM was performed, the Olympus IX81 microscope equipped with a confocal light path (Wave-Fx; Quorum) based on a modified Yokogawa CSU-10 head (Yokogawa Electric Corporation, Calgary, AB, Canada) was used for imaging.
Neutrophil depletion-reinfusion
Neutrophil were depleted by one intraperitoneal injection of 150 lg anti-GR-1 antibody (e-bioscience) 24 hr prior to the desired depletion time. 41 For neutrophil reinfusion experiments, neutrophils were either unstimulated or stimulated with 500 nM PMA for 1 hr at 378C in the presence of 20 lg anti-mouse CD29 antibody (Acris) or anti-mouse IgG1 (isotype control) or 1000 u DNase I. 10 6 neutrophils of each condition were injected intrasplenically in neutrophil-depleted mice.
Statistics
One-way ANOVA with post-hoc multiple comparisons was employed to compare mean values between different groups, with a p values < 0.05 set as a threshold for statistical significance. All data is presented as mean 6 SEM.
Results
Tumor-NETs interaction is a protein-protein interaction mediated by integrins
Recent data from our lab has shown that tumor cells adhere to NETs both in vitro and in vivo 27 however the mechanism by which this process occurs remains unknown. We show that the tumor cell-NET adhesion is not affected by pH changes in the surrounding media ( Fig. S1 ) indicating that the interaction is not electrostatic in nature. We therefore moved on to test whether tumor cell adhesion on NETs is protein-mediated. NETs were isolated from human blood and plated into wells. A549 tumor cells were then added on to the NET monolayer and adhesion was quantified. Addition of DNAse 1 led to a significant decrease in adhesion to 10.63% compared to adhesion on NETs alone (p < 0.001). Similarly, in the presence of proteinase K, A549 cell adhesion decreased to 13.38% (p < 0.001) compared to NETs alone while there was no significant decrease in adhesion in the presence of vehicle control (64.2% adhesion relative to NETs
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alone) (Figs. 1a and 1b). After establishing that binding of tumor cells to isolated NETs in vitro is mediated by proteinprotein interactions, and knowing the predominant role of integrins in tumor cell interactions with ECM components and their role in cancer progression, we hypothesized that integrins could mediate tumor cells-NET interactions. Accordingly, as in the previous experiments, A549 adhesion on isolated human NET monolayers was quantified in the presence of RGD peptide, a known competitive inhibitor of at least 8 of the 20 known integrin heterodimers. 42 In the presence of RGD peptide, A549 adhesion to NETs decreased significantly reaching 53.64% (p < 0.01) and 43.75% (p < 0.0001) of adhesion compared to vehicle control in the presence of 10 lM and 20 lM of RGD peptide respectively (Figs. 1c and 1d) confirming that RGD-sequence containing integrins at least partially mediate tumor cell-NET interactions.
Tumor-derived b1 integrin mediate adhesion to NETs in vitro
The RGD peptide, as stated previously, can block a number of integrins heterodimers, most of which carry the b1 subunit; we therefore sought to determine whether b1 could be the integrin factor responsible for the integrin-mediated cancer cell adhesion to NETs in vitro. We started by looking at b1 integrin expression on A549 cancer cells. To do so, flow cytometry testing of A549 cells for b1 integrin expression revealed that 99.98% of cells expressed the b1 integrin surface receptor (Fig. 2a) . We therefore repeated the static adhesion assay of A549 cancer cells on isolated human NETs and in some conditions inhibited tumor-derived b1 integrin by pre-incubating tumor cells with function blocking b1 integrin antibody before addition onto the NET monolayer. This resulted in a 39.65% (p < 0.0001) decrease in tumor cell adhesion relative to untreated cells; conversely, preincubation of A549 cancer cells with IgG1 isotype control did not result in significant decreased in tumor cell adhesion to NETs (98.05% compared to untreated cells) (Fig. 2b) . Moreover, flow cytometry was used to verify siRNA silencing of b1 integrin expression on A549 cancer cells and shows a time-dependent decrease in surface b1 integrin expression reaching 99.96% cell surface b1 integrin expression at 24 hr (green peak) and 69.66% cell surface b1 integrin expression at 48 hr (red peak) post transfection compared to 0% for unstained A549 cells (white peak) and 100% for control siRNA transfected A549 cells (blue peak) (Fig. 2c) . In keeping with previous results, b1 siRNA treated cells demonstrated 53.03% relative adhesion (p < 0.01) compared to wild type A549 cells and 47.83% adhesion relative to control siRNA treated cells (p < 0.01) and there was no significant difference between adhesion of untreated cells and cell treated with control siRNA on NETs (88.52% adhesion of untreated cells relative to control siRNA adhesion) (Fig. 2d) .
To demonstrate that tumor-derived b1 integrin binding to NETs results in subsequent integrin activation and clustering, we sought to demonstrate integrin-mediated tumor cell binding to NETs results in FAK complex activation. To do so, A549 cells were allowed to adhere on a NET monolayer or plain glass coverslip for 90 min followed by staining for p-FAK, the active phosphorylated form of the protein complex. A549 cells co-incubated with NETs showed strong p-FAK staining whereas cells that were left to adhere on plain glass did not show any p-FAK staining (Fig. 2e) . Western blot was finally performed to confirm and quantify FAK complex activation following binding of tumor cells to NETs. Accordingly, A549 tumor cells were serum starved for 24 hr and NETs were added to the serum-starved cells. The interaction was arrested at 30, 90, 120 and 180 min and levels of FAK as well as p-FAK quantified: FAK activation was represented by p-FAK/FAK ratio. Untreated A549 cells similarly serum-starved for 24 hr were used as a negative control. Addition of NETs to A549 cells led to a 66.67% increase in p-FAK/FAK ratio (p < 0.01) at 30 min after the initial contact and decreased thereafter reaching the baseline levels at around 120 min post initial contact (Fig. 1f) confirming that cancer cell adhesion to NETs results in integrin clustering and activation.
Tumor-derived b1 mediates cancer cells-NETs adhesion in vivo
After confirming that b1 integrins are expressed on cancer cells and demonstrating their roles in mediating adhesion of cancer cells to NETs in vitro, we sought to confirm our findings in an in vivo mouse model. In vivo NET production is induced by subjecting mice to cecal ligation puncture (CLP) which causes a significant abdominal septic response and widespread NET deposition in liver sinusoids and lung capillaries as previously shown by our group. 27 24 hr following CLP to induce intravascular NET formation, A549 cells were injected intrasplenically in mice and adhesion of A549 cells to liver sinusoids measured with intravital epifluorescence microscopy 10 min after injection. A mean value was obtained from averaging fluorescent cells seen in 8-10 hpfs per imaged mouse. Mice were divided into two groups, one of which underwent CLP and another that underwent sham surgery. To assess the role of tumor-derived b1 integrin, siRNA silencing of b1 integrin on A549 cancer cells was performed as above. Some mice received wild type (WT) A549 cells while others received siRNA b1 integrin KD cells 24 or 48 hr post transfection. Finally, some mice received DNAse 1 treatment to degrade intravascular NETs. Compared to sham, CLP-treated mice had a significant increase of A549 cancer cell adhesion (284.6% relative to sham, p < 0.0001). In CLP treated mice, A549 cancer cell adhesion mildly decreased when b1 siRNA knock down at 24 hr were used compared to WT A549 cell (70.27% relative to WT A549 in CLP mice), this decrease however became significant that were allowed to be in contact with NETs showed a 66.67% increase in p-FAK/FAK ratio at 30 min of interaction compared to untreated cells, which decreased to baseline levels by 120 min. *p < 0.01 versus untreated cells and **p < 0.001 versus NET and isotype control. Significance was determined using Kruskal-Wallis test with post hoc analysis. Each condition was performed in triplicate and each experiment was repeated two to three times.
Tumor Immunology and Microenvironment
when b1 siRNA knock down at 48 hr were injected (34.21% relative to WT A549 cells in CLP mice, p < 0.001) (Figs. 3a  and 3b) . Injection of cells treated with control siRNA did not cause a significant change in A549 cancer cell adhesion compared to WT cells (105.4% compared to WT A549 cells in CLP) (Fig. 3a) . While DNAse 1 administration to CLP mice decreased WT A549 cells adhesion to a level almost comparable to that of sham mice (51.35% relative to WT cells in CLP), it did not significantly affect A549 cell adhesion to hepatic sinusoids in CLP mice receiving b1 siRNA KD cells compared to mice that received the same KD cells without DNAse (54.05% relative to WT A549 cells in CLP, p < 0.01) (Fig. 3a) . Finally, injection of b1 siRNA knock down cells did not affect significantly A549 adhesion to hepatic sinusoids in sham treated mice (162.5% relative to WT cells in sham) (Fig. 3a) .
NETs b1 integrin is expressed on NETs and mediates adhesion to tumor cells in vitro
After demonstrating that tumor-derived b1 integrin is involved in tumor cell-NET adhesion; we sought to investigate whether b1 integrins decorating NETs can also contribute to this process. To do so, NETs were isolated from human neutrophils and allowed to coat glass coverslips and staining for extracellular DNA as well as b1 integrin performed. Extensive co-localization between extracellular DNA and b1 integrin was demonstrated, suggesting that b1 integrins are strongly expressed on NETs DNA webs in vitro (Fig. 4a) . Presence of b1 integrin on isolated cell-free NETs was also confirmed by Western blotting (Fig. 4b) . To show that this is not an artifact of our NETs purification, we isolated neutrophils and stimulated them with PMA and observed colocalization of b1 integrin on NETs (Fig. 4c) . We then turned our attention to determining if NET-derived b1 integrins play a role in tumor cell binding on NETs. To do so, 4B4 function blocking a b1 integrin antibody was added to isolated NETs were prior to their co-incubation with A549 cancer cells. In conditions where NETs were exposed to 4B4, A549 adhesion on NET monolayers decreased to 57.52% compared to untreated NETs (p < 0.001) while addition of IgG1 isotype control to isolated NETs prior to addition of A549 cancer cells did not significantly affect cancer cell adhesion to the NET monolayers (104.5% relative addition compared to untreated NETs) (Fig. 4d) .
NETs b1 integrin expression increases during systemic inflammation in vivo
After confirming that b1 integrins are expressed on NETs and demonstrating their role in mediating adhesion to cancer cells in vitro, we sought to confirm our findings in vivo in the context of a systemic infection. C57BL/6 mice were subjected to CLP then injected with fluorescent antibodies for neutrophils, b1 integrin and several NET components 24 hr later and imaged using intravital microscopy. To selectively visualize NET-derived b1 integrin, the fluorescent antibody used for b1 integrin was specific for the intracellular C-terminal portion of the b1 subunit, which would therefore not stain any b1 integrin receptor on the surface of surrounding cells. Interestingly, imaging revealed extensive neutrophil deposition within hepatic sinusoids after CLP with surrounding dense extracellular DNA staining, which were thought to represent NETs (Fig. 4e) . b1 integrin staining strongly co-localized in areas of extracellular DNA staining further supporting their NET-derived origin (Fig. 4e) . To confirm that b1 integrins seen in the liver in the context of inflammation are NET-derived; we repeated the previous experiment and quantified the b1 integrins antibody fluorescence in CLP, sham or neutrophil-depleted mice 24 hr prior . b1 integrin inhibition on NETs leads to decreased cancer cell adhesion to liver sinusoids in vivo. Following neutrophil isolation from healthy C57BL/6 mice, neutrophils were stimulated to undergo NETosis and were simultaneously incubated with either b1 integrin anti-CD29 antibody or anti-IgG1 isotype control for 1 hr before being re-infused into neutrophil-depleted mice. 20 min later, A549 cancer cells were injected intrasplenically and number of adherent fluorescent cells in 10hpf/mouse counted. Representative images of the intravital microscopy performed on the depletion-reinfusion experiment are shown in (a) and means 6 SEM are plotted in (b) for each group. Five mice were used per group and the experiment was repeated twice. The number of adherent cell per condition was counted blinded.
to CLP. Mice that underwent CLP showed a 365.3% b1 integrin fluorescence compared to mice that underwent sham surgery (p < 0.001). When CLP was preceded by neutrophil depletion however, there was no significant change in b1 integrin expression compared to sham treated mice (135.9% relative to sham) (Fig. 1f) . We were therefore able to conclude that NET-derived b1 integrin expression increases in hepatic sinusoids in the context of inflammation.
b1 integrin inhibition on NETs leads to decreased cancer cell adhesion to liver sinusoids in vivo
To identify the role of NET-derived b1 integrins on cancer cells adhesion in hepatic sinusoids, a series of neutrophil depletion-reinfusion experiment was performed. 27, 43 Neutrophil depletion was achieved by intraperitoneal injection of anti GR-1 antibody in mice, which has been previously shown to cause 95% depletion of circulating neutrophils 24 hr later. 41 24 hr later, neutrophils were isolated from C57BL/ 6 syngeneic mice and stimulated with PMA for 1 hr to undergo NETosis ex-vivo. To block b1 integrin expression on NETs, isolated neutrophils were simultaneously treated with either function blocking b1 integrin antibody or corresponding anti-IgG1 isotype control or with DNAse 1. After allowing incubation for 1 hr, 10 6 neutrophils were intrasplenically re-injected in neutrophil depleted mice. Mice were kept under general anesthesia for 10 min then intrasplenic injection of 10 5 CFSE-tagged A549 cancer cells was performed and in vivo sinusoidal arrest of cancer cells assessed by IVM imaging 20 min later (Fig. 5a) . Inhibition of b1 integrins on NETs prior to reinfusion in mice lead to a significant decreased in A549 cancer cell adhesion within hepatic sinusoids compared to PMA-stimulated untreated control (mean adhesion 3.3 for PMA alone group compared to 0.17 for the CD29 group, with n 5 3 mice per group, p < 0.05) (Fig. 5b) . This decrease was not observed in the isotype control group (mean adhesion 5.06, n 5 8 mice) and DNAse 1 was able to significantly decrease that adhesion (mean adhesion 0.88, n 5 5 mice, p < 0.05) (Fig. 5b) . Taken together, this data demonstrates that NET-derived b1 integrins play an important role in cancer cell adhesion to hepatic sinusoids.
Tumor-derived and NET b1 integrins co-localize in vitro As b1 integrins from both cancer cells and NETs seem to partially mediate adhesion between these entities, we examined whether integrins could be interacting with each other. A549 cells were labeled with Alexa-fluor 647 tagged anti b1 integrin antibody and NETs with Alexa-fluor 555 tagged b1 integrin antibody, and then co-incubated together. After DNase 1 treatment, confocal microscopy images revealed a close relationship between NET-derived b1 integrins and b1 integrins on cancer cell membranes (Fig. 6a) . Quantitative assessment of b1 integrin-b1 integrin co-localization was then carried out; similarly to the previous experiment, NETs were pre-labeled with nonfunction blocking Alexa-fluor 555 tagged b1 integrin antibody and added to A549 cell monolayer and allowed to interact for 90 min as shown in Figure 6b . In some conditions, A549 cells forming the monolayers were left untreated, while in others A549 cells were treated with function blocking 4B4 antibody or an isotype control. Following co-incubation of NETs on A549 monolayers, 1000 Units DNAse 1 was added to dissolve any unbound material and cells washed, leaving only Netderived fluorescently labeled b1 integrins specifically bound to cancer cells. Alexa-fluor 555 fluorescence was quantified at this point and plotted (Fig. 6c ) and representative confocal images are shown (Fig. 6d) . We showed that inhibition of b1 integrins on A549 cancer cells lead to 51.63% decrease (p < 0.001) in NET-derived b1 integrin fluorescence compared to untreated A549 cells, whereas treatment with IgG1 isotype control did not show a significant change in fluorescence (142.86% relative adhesion relative to untreated cells) (Figs. 6c and 6d) . The observed decrease in NET-derived b1 integrin binding when tumor-derived b1 integrin is blocked suggests that the two integrin entities might interact together.
Discussion
The interaction between inflammatory and malignant processes has been at the center of many studies in the last years and seems to be both a complex and dynamic one. The discovery of NETs first in host defenses then in various disease states raised the question of whether the increased release of NETs from activated neutrophils in the context of inflammation can contribute to the increase in cancer recurrence and worsened oncological outcomes in cancer patients. Accordingly, data from our group recently implicated NETs in increased circulating tumor cell adhesion to distant organs 27 and showed that circulating NETS and NET-derived proteins can exert a role on tumor progression and spread. 44 The work presented here complements the existing literature by shedding new light on the mechanisms through which NETs interact with circulating tumor cells and therefore affect cancer progression. We identified b1 integrins as an abundant constituent of NETs and we were able to show both in vitro and in vivo that b1 integrins, expressed on both tumor cells and NETs, play a significant role in mediating the adhesion of cancer cells to NETs.
One important element to point out is that the inhibition of b1 integrins through either antibodies or siRNA does not completely inhibit cancer cell adhesion to NETs. This is not surprising as NETs are in fact decorated by hundreds of proteins many of which might also contribute to cancer cell adhesion and tumorigenesis and b1 integrins are probably only one of the players recognized to this date. Moreover, we have repeatedly demonstrated in this body of work frequent and close colocalization between both NET-and cancer cell-derived b1 integrins especially in the context of inflammation, suggesting possible interactions between these entities. Integrins however are known to be obligate heterodimers, with b subunits always dimerizing with an alpha subunit. 28 The significance of this colocalization is therefore still unclear, with a potential hypothesis being an indirect interaction of the b1 subunits of tumors and NETs through a potential "bridging" molecule, such as ECM components, which remains to be explored. Ex-vivo stimulation of neutrophils followed by b1 integrin inhibition and reinfusion in the depletion reinfusion experiments is quite a complex model but its use was necessary since b1 knock down mice are not viable. Moreover, work published in the field has used this method successfully in the past and we were able to use it in our lab in the past. 43 Another alternative to this was to induce NETosis in vivo by performing CLP and later inhibiting NET-associated b1 integrins by injecting anti-b1 integrin antibody in the mice. However, the depletion-reinfusion model allows a much more specific targeting of NET-derived b1 integrins and therefore allows to more precisely determining the exact role of these integrins in that experiment.
Finally, it is crucially important to understand the mechanism of interactions between tumor and NET-derived b1 integrins but what is also as interesting is to look at the postadhesive events that eventually result in increased in gross metastases remain to be elucidated as it remains unclear how increased cancer cell adhesion to NETs in distant organ microvasculature leads to gross metastasis. In a recent publication, Tohme et al. implicated NETs as potential contributors to metastatic cancer progression in the context of surgical stress. 45 Indeed, they observed NET formation in the liver following surgical stress, and they found that this was associated with an increase in liver metastasis. Following treatment of those mice with DNase or PAD4 inhibitors (or using a PAD4 deficient mice) they observed an improved oncological outcome in vivo. This is in line with the increase adhesion we observe in our CLP model which should lead to increased metastatic load in the liver as compared to sham.
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DNase treatment leads to decrease adhesion which should lead to a decrease in liver metastasis.
In conclusion, the work presented here complements preexisting literature linking inflammatory states and cancer progression and is the first to examine the mechanism by which NETs can interact with, trap and adhere to circulating tumor cells, eventually leading to increased metastasis. It also proposes a novel facet of the already complex role of integrins in cancer progression by demonstrating the role of b1 integrins as important players in CTC-NET interactions.
